10.8 months against 8.6: a virus-based treatment for pancreatic cancer reports results
What happened
On 30 September 2026, the journal Nature Medicine published the full results of a trial called VIRAGE. The trial tested a new kind of treatment for advanced pancreatic cancer. The treatment is a modified virus, given by a drip into a vein. Its scientific name is zabilugene almadenorepvec, and it was studied under the code VCN-01. The idea behind it is unusual. The virus is engineered to grow inside cancer cells and break them apart. It also makes an enzyme called hyaluronidase, which loosens the dense, tough tissue that surrounds pancreatic tumours. That tough shell is one reason pancreatic cancer is so hard to treat: it keeps chemotherapy out. VIRAGE was a phase 2b trial. It was randomised, meaning patients were assigned by chance to one of two groups, and open-label, meaning everyone knew which treatment they were getting. There were 48 patients in each group, 96 in total in the main analysis. One group received standard chemotherapy, gemcitabine with nab-paclitaxel. The other group received the same chemotherapy plus the modified virus. All patients had pancreatic cancer that had spread, and none had been treated for it before. The headline figures were as follows. Median overall survival was 10.8 months with the virus added, against 8.6 months with chemotherapy alone. Median progression-free survival, the time before the cancer grew again, was 7.0 months against 4.6 months. Among patients whose tumours responded, the response lasted a median of 11.2 months against 5.4 months. The researchers concluded that the combination deserves to be tested in a larger, blinded phase 3 trial.
Why this matters
Pancreatic cancer has one of the worst outlooks of any common cancer. It often causes few clear symptoms until it has already spread. By the time it is found, surgery is frequently no longer possible. For people whose cancer has spread, chemotherapy can slow it and ease symptoms, but average survival is measured in months rather than years. Progress has been slow and hard-won. Several promising ideas have failed at the final hurdle. That is why any signal of benefit gets attention. An extra two months of median survival may sound small written down. For a family planning around a diagnosis, it is not nothing. The longer-term interest is in the approach itself. If loosening the tissue around a pancreatic tumour really does let chemotherapy work better, that principle could matter beyond this one drug. It also matters that this result is being reported in a leading journal with its numbers in the open, including the parts that are less flattering. That is how good science is supposed to look.
What the evidence actually says
This is a promising early result, not a new treatment you can ask for. The detail matters. Start with the main result. Median overall survival was 10.8 months against 8.6 months. The hazard ratio was 0.57, with a 95% confidence interval of 0.34 to 0.96, and a p value of 0.055. That p value is the important caveat. By the usual convention, a result is called statistically significant when the p value is below 0.05. At 0.055, this one just misses. In plain terms: the survival difference looks real, but the trial was not large enough to rule out chance by the standard yardstick. The progression-free survival result was stronger. A hazard ratio of 0.55, confidence interval 0.34 to 0.88, p value 0.011. That does clear the usual bar. So did the duration of response: hazard ratio 0.22, p value 0.004. Longer-term survival figures also favoured the combination. At 15 months, 35.5 per cent of patients on the combination were alive against 12.8 per cent on chemotherapy alone. At 18 months, the figures were 31.1 per cent against 8.5 per cent. On safety, serious side effects occurred in 22.6 per cent of patients. The most common problems were fever, flu-like symptoms, raised liver enzymes and a drop in platelets, the cells that help blood clot. Two patients died during the study, one in each group, and neither death was judged to be caused by the treatment. The biggest limitation is size. Ninety-six patients is small. The trial was also open-label, so neither patients nor doctors were blinded, which can influence how outcomes are assessed. This is why the authors call for a blinded phase 3 trial rather than declaring the question settled. So the fair reading is: encouraging, biologically interesting, and not yet proven.
Practical advice
If pancreatic cancer affects you or someone close to you, here is how to use news like this sensibly. Take it to your own team. Your oncologist knows your diagnosis, your test results and what treatments are realistic for you. A trial result in a journal cannot tell you whether something is suitable for one person. Ask about clinical trials. In the UK, you can ask your oncology team whether any trials are open that you might be eligible for. Being in a trial is not a last resort; for many cancers it is one route to newer treatments under close monitoring. Be careful with anything offered outside that route. If a clinic abroad offers a virus-based or similar treatment for a fee, ask what trial it is part of, who regulates it, and what published evidence supports it. Genuine research does not usually require you to pay out of pocket. Ask about symptom control as well as treatment. Pain relief, help with digestion, and support with weight loss and appetite make a real difference to how people feel day to day. Use the established charities for support and information. Pancreatic Cancer UK and Macmillan Cancer Support both offer specialist nurse helplines, free of charge. And give yourself permission to take information in slowly. You do not have to understand every number in a trial report to ask good questions.
What to know
The VIRAGE phase 2b trial tested a modified virus, zabilugene almadenorepvec, given with standard chemotherapy as a first treatment for pancreatic cancer that had spread. Ninety-six patients were split evenly between the combination and chemotherapy alone. Median overall survival was 10.8 months with the combination against 8.6 months without, a difference that narrowly missed statistical significance at a p value of 0.055. Progression-free survival, 7.0 months against 4.6, and duration of response, 11.2 months against 5.4, did reach significance. Serious side effects occurred in 22.6 per cent of patients, and neither of the two deaths during the study was linked to treatment. The authors say the findings justify a larger blinded phase 3 trial. This is not yet an approved or available treatment in the UK. Sources: Nature Medicine, "Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial", 30 September 2026, https://www.nature.com/articles/s41591-026-04705-y ; Targeted Oncology, "Zabilugene Almadenorepvec Plus Chemo Shows Survival Gains in Metastatic PDAC", https://www.targetedonc.com/view/zabilugene-almadenorepvec-plus-chemo-shows-survival-gains-in-metastatic-pdac ; Theriva Biologics press release, https://www.biospace.com/press-releases/theriva-biologics-announces-publication-of-the-results-from-the-virage-phase-2b-clinical-trial-of-vcn-01-in-metastatic-pancreatic-cancer This article is for general information and does not replace advice from a doctor, oncologist, pharmacist or other qualified healthcare professional. Decisions about cancer treatment should always be made with your own clinical team.
Related articles
Six hours, not never: the ICU filter notice the MHRA issued today
The UK's medicines and devices regulator has issued a new safety notice to hospitals, and it is about timing. On 13 October 2026 the Medicines and Healthcare p…
Eight pages to a minister: what the data guardian says trust is worth
On 12 October 2026, the government published a letter about who should be trusted with NHS patient data. It was written by Dr Nicola Byrne, the National Data G…
Update: the tests came back, and it was not plague
This is a follow-up to a story we covered on 5 October, when nearly 200 people were being monitored after the death of a laboratory worker in Siberia. There has…